Healthcare Industry News: paclitaxel
News Release - August 29, 2007
Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007NATICK, Mass., Aug. 29 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2007, which runs from September 1 to 5 in Vienna, Austria.
The Company plans to announce five-year results from the TAXUS II clinical trial. The data are expected to build on the strong body of clinical evidence supporting the continued efficacy and long-term safety profile of the TAXUS® paclitaxel-Eluting Stent System. In addition, the Company will announce partial one-year data from Phases II and III of the OLYMPIA registry, designed to study real-world outcomes of its TAXUS® Liberte(TM) paclitaxel-Eluting Stent System. The Company anticipates the data will further reinforce the safety and efficacy of its second-generation drug-eluting stent system.
Details of the Company's activities at ESC 2007 are below.
Schedule of events (all times are Vienna time)
Sunday, September 2
-- OLYMPIA Phase II & III one-year data. Preliminary results from Phases II & III of the global OLYMPIA registry will be presented by Martyn Thomas, M.D., F.R.C.P., at 4:45 p.m., in the Helsinki Room (Zone 2). OLYMPIA is a prospective, multi-center, multi-phased registry with a planned enrollment of up to 27,000 patients, making it the largest study of its kind worldwide. The registry is designed to analyze real- world clinical outcomes data for Boston Scientific's second-generation TAXUS Liberte paclitaxel-Eluting Stent System. Results from more than 7,000 Phase II and III patients will focus on safety and efficacy, and will highlight outcomes within the high-risk diabetic subset. The Company plans to issue a press release at this time.
Tuesday, September 4
-- TAXUS II long-term data. At 9:45 a.m., five-year clinical follow-up results from the TAXUS II clinical trial will be presented by Antonio Colombo, M.D., the study's principal investigator, in the Helsinki Room (Zone 2). TAXUS II is a randomized, double-blind, controlled study of the safety and efficacy of the TAXUS paclitaxel-Eluting Coronary Stent, in which two sequential cohorts of patients with standard risk, de novo coronary artery lesions were treated with different dose formulations versus a bare-metal stent control group. The Company plans to issue a press release at this time.
-- Cardiac Rhythm Management Workshop Session. At 12:45 p.m., the Company will host a workshop entitled "Cardiac Resynchronisation Therapy: all you need to know to maximize patient follow-up," in the Cairo Room (Zone 2). The session will address the current status of CRT, the value of HF diagnostics after device implant, and hemodynamic optimization during CRT.
-- Symposium on Drug-Eluting Stents. At 2:00 p.m., the Company will host a symposium entitled "What's the evidence for using drug-eluting stents in your patients," chaired by H.D. Glogar, M.D., and Donald S. Baim, M.D., in the Brussels Room (Zone 4). The symposium will focus on current treatment options for coronary artery disease, latest challenges in ULMCA (Unprotected Left Main Coronary Artery) with PCI, evidence-based medicine for diabetics, real world data, and future outlook for DES.
Wednesday, September 5
-- TAXUS in Women study. Results from the TAXUS WOMAN study, a gender specific sub-group analysis of the TAXUS II - VI trials, will be presented in a poster session at 10:05 a.m. The aim of this study is to assess the relative efficacy of the TAXUS paclitaxel-eluting stents compared to bare-metal stents in women undergoing coronary revascularization. The pooled results of the women enrolled in these TAXUS trials were analyzed on an intention-to-treat basis and compared with the corresponding endpoints in men.
Boston Scientific will present its latest innovations at booth B225 in the Exhibition Zone 3.
About the European Society of Cardiology Congress
The European Society of Cardiology Congress 2007 will bring together the world's leading cardiologists to present the most relevant scientific developments in the field on issues including diagnosis, management and treatment of cardiovascular disease. The event in Vienna, Austria is expected to attract more than 20,000 medical professionals.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com .
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our growth strategy, our expense reduction initiatives, our capital needs and expenditures, potential acquisitions and divestitures, our debt repayment strategy, our operational strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Exercises Option to Acquire Farapulse, Inc.
Boston Scientific Completes CE Mark for EXALT(TM) Model B Single-Use Bronchoscope
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2(TM) Aortic Valve System